Ripple Therapeutics Appoints Jonathan Talamo, MD, to Chair of the Board

Ripple Therapeutics announced that Jonathan Talamo, MD, has been appointed as the new Chair of its Board of Directors. 

Dr. Talamo is internationally known as an experienced surgeon and thought leader in ophthalmology. Following 25 years in clinical practice, Dr. Talamo served as the Chief Medical Officer at Ocular Therapeutix, where he oversaw development programs in multiple therapeutic areas, including post–cataract surgery inflammation, dry eye, allergy, glaucoma and retinal vascular diseases. Most recently, he served as  Chief Medical Officer and Worldwide VP of Clinical and Medical Affairs at Johnson and Johnson Vision. While at J&J, Dr. Talamo helped lead the integration of Abbott Medical Optics as well as the development and launch of numerous innovative products.

“It’s an exciting time at Ripple Therapeutics, with licensing agreements in place and a clinical trial well underway for IBE-814 IVT (treating DME and RVO) and progress towards the clinic with RTC-1119 (treating glaucoma)” Dr. Talamo said in a company news release. “I’m looking forward to working even more closely with the Ripple Board and team to bring important, proprietary extended-release ophthalmic therapeutics to market that address significant unmet needs for patients and clinicians.”

“With his clinical experience as an ophthalmologist and industry experience with both large and small companies, Jon has already brought tremendous insight to our Board," said Tom Reeves, President and CEO, Ripple Therapeutics. “Now as Chair, we look forward to his leadership as we work to realize our vision of developing novel therapeutics that provide better outcomes for patients, easier management of care for physicians and lower costs for payors.”